Neonatal abstinence syndrome diagnosis is predictive of maternal mortality

  • Guttmann A & al.
  • PLoS Med
  • 1 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Neonatal abstinence syndrome (NAS) may predict long-term maternal mortality.

Why this matters

  • The peripartum period is an opportunity to improve maternal health.
  • Ongoing support of mothers with opioid use disorder may prevent increased risk for maternal mortality.

Key results

  • Mothers with infants born with NAS had higher mortality rates (11-12 times) compared with controls.
  • The majority of deaths were from preventable causes such as intentional and unintentional injuries.
  • This difference persisted over time.

Study design

  • Population-based parallel-cohort study.
  • Administrative health data were used to develop parallel cohorts of mother-infant dyads in England and Ontario between 2002 and 2012.
  • Dyads with NAS (n=18,543) were compared with controls (n=5,149,237).
  • Primary exposure was a live birth of an infant with NAS.
  • Main outcome was all deaths among mothers following their delivery date.
  • Funding: Ontario Ministry of Health and Long-Term Care, National Institute for Health Research Policy Research Programme, Administrative Data Research Centre for England, Farr Institute of Health Informatics Research London, Medical Research Council; others.

Limitations

  • Potential linkage errors.
  • Misclassification of mothers using opioids whose babies did not develop NAS.